Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
08 2020
Historique:
received: 22 04 2020
revised: 08 05 2020
accepted: 12 05 2020
pubmed: 15 5 2020
medline: 25 6 2020
entrez: 15 5 2020
Statut: ppublish

Résumé

An increased risk of venous thromboembolism (VTE) in patients with COVID-19 pneumonia admitted to intensive care unit (ICU) has been reported. Whether COVID-19 increases the risk of VTE in non-ICU wards remains unknown. We aimed to evaluate the burden of asymptomatic deep vein thrombosis (DVT) in COVID-19 patients with elevated D-dimer levels. In this prospective study consecutive patients hospitalized in non-intensive care units with diagnosis of COVID-19 pneumonia and D-dimer > 1000 ng/ml were screened for asymptomatic DVT with complete compression doppler ultrasound (CCUS). The study was approved by the Institutional Ethics Committee. The study comprised 156 patients (65.4% male). All but three patients received standard doses of thromboprophylaxis. Median days of hospitalization until CCUS was 9 (IQR 5-17). CCUS was positive for DVT in 23 patients (14.7%), of whom only one was proximal DVT. Seven patients (4.5%) had bilateral distal DVT. Patients with DVT had higher median D-dimer levels: 4527 (IQR 1925-9144) ng/ml vs 2050 (IQR 1428-3235) ng/ml; p < 0.001. D-dimer levels > 1570 ng/ml were associated with asymptomatic DVT (OR 9.1; CI 95% 1.1-70.1). D-dimer showed an acceptable discriminative capacity (area under the ROC curve 0.72, 95% CI 0.61-0.84). In patients admitted with COVID-19 pneumonia and elevated D-dimer levels, the incidence of asymptomatic DVT is similar to that described in other series. Higher cut-off levels for D-dimer might be necessary for the diagnosis of DVT in COVID-19 patients.

Identifiants

pubmed: 32405101
doi: 10.1016/j.thromres.2020.05.018
pii: S0049-3848(20)30190-0
pmc: PMC7219400
pii:
doi:

Substances chimiques

Anticoagulants 0
Biomarkers 0
Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-26

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
Thromb Haemost. 2004 Apr;91(4):655-66
pubmed: 15045125
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
J Vasc Nurs. 2015 Sep;33(3):95-9
pubmed: 26298612
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Thromb Res. 2020 May;189:5-12
pubmed: 32126379
Lancet Haematol. 2020 May;7(5):e362-e363
pubmed: 32278361
Lancet. 2017 Jul 15;390(10091):289-297
pubmed: 28549662
Thromb Res. 2012 Oct;130(4):591-5
pubmed: 22694877
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
Ann Intern Med. 2001 Jul 17;135(2):98-107
pubmed: 11453709
Thromb Haemost. 2020 May;120(5):876-878
pubmed: 32246450
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA. 2014 Mar 19;311(11):1117-24
pubmed: 24643601
Knee. 2009 Jan;16(1):18-21
pubmed: 19008109
N Engl J Med. 2019 Nov 28;381(22):2125-2134
pubmed: 31774957
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666

Auteurs

P Demelo-Rodríguez (P)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain; Gregorio Marañón Sanitary Research Institute, Madrid, Spain.

E Cervilla-Muñoz (E)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.

L Ordieres-Ortega (L)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.

A Parra-Virto (A)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.

M Toledano-Macías (M)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.

N Toledo-Samaniego (N)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.

A García-García (A)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.

I García-Fernández-Bravo (I)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.

Z Ji (Z)

School of Medicine, Universidad Complutense de Madrid, Spain; Respiratory Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

J de-Miguel-Diez (J)

School of Medicine, Universidad Complutense de Madrid, Spain; Gregorio Marañón Sanitary Research Institute, Madrid, Spain; Respiratory Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Respiratory Diseases CIBER (CIBERER), Madrid, Spain.

L A Álvarez-Sala-Walther (LA)

School of Medicine, Universidad Complutense de Madrid, Spain; Gregorio Marañón Sanitary Research Institute, Madrid, Spain.

J Del-Toro-Cervera (J)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain; Gregorio Marañón Sanitary Research Institute, Madrid, Spain.

F Galeano-Valle (F)

Venous Thromboembolism Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain; Gregorio Marañón Sanitary Research Institute, Madrid, Spain. Electronic address: paco.galeano.valle@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH